A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
PD-1 and CTLA-4 antibodies offer great hope for cancer immunotherapy. However, many patients are incapable of responding to PD-1 and CTLA-4 blockade and show low response rates due to insufficient immune activation. The combination of checkpoint blockers has been proposed to increase the response ra...
Saved in:
Main Authors: | Wenjie Zhai (Author), Xiuman Zhou (Author), Hongfei Wang (Author), Wanqiong Li (Author), Guanyu Chen (Author), Xinghua Sui (Author), Guodong Li (Author), Yuanming Qi (Author), Yanfeng Gao (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy
by: Yuzhen Qian, et al.
Published: (2024) -
Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response
by: Chen Ling, et al.
Published: (2022) -
Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
by: Xiaoshuang Niu, et al.
Published: (2023) -
The use of cyclic peptide antigens to generate LRP8 specific antibodies
by: Maria A. Argiriadi, et al.
Published: (2023) -
Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway
by: Yumiao Zhao, et al.
Published: (2021)